3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
47
Neoplasm Metastasis
9
Neoplasms
8
Prostatic Neoplasms
7
Brain Neoplasms
7
Endometrial Neoplasms
6
Glioblastoma
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Meningioma
3
Carcinoma, Renal Cell
3
Sarcoma
2
Recurrence
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Oligodendroglioma
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Liposarcoma
2
Hematologic Neoplasms
2
Glioma
2
Breast Neoplasms, Male
2
Breast Diseases
2
Breast Cancer Female
2
Venous Thromboembolism
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Unilateral Breast Neoplasms
1
Interventions
Cisplatin
86
Radiotherapy
71
Paclitaxel
50
Fluorouracil
38
Carboplatin
36
Drug Therapy
32
Neoadjuvant Therapy
23
toripalimab
19
tislelizumab
18
pembrolizumab
17
camrelizumab
17
Irinotecan
17
Esophagectomy
17
Surgical Procedures, Operative
16
Radiation
16
Docetaxel
16
sintilimab
15
Oxaliplatin
14
130-nm albumin-bound paclitaxel
14
nimotuzumab
11
TP protocol
11
S 1 (combination)
11
Radiotherapy, Intensity-Modulated
11
Cetuximab
11
Capecitabine
11
Albumin-Bound Paclitaxel
10
apatinib
9
Leucovorin
9
Immune Checkpoint Inhibitors
8
nedaplatin
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Esophageal Squamous Cell Carcinoma
×
abemaciclib
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled